Stockreport

Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 S...

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted to faster development, manufacturing efficiency, and addressing prevalent diseases. [Read more]